Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 19/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.72 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.72 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9484593 | 1.00 | P2RX7 (0.87) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL15265405 | 0.90 | P2RX7 (0.72) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL28912764 | 0.90 | P2RX7 (0.72) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL29412081 | 0.90 | P2RX7 (0.72) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9483169 | 0.90 | P2RX7 (0.71) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9483177 | 0.90 | P2RX7 (0.71) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9484609 | 0.89 | P2RX7 (0.70) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9483404 | 0.89 | P2RX7 (0.70) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9484617 | 0.89 | P2RX7 (0.70) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL9483407 | 0.89 | P2RX7 (0.70) | P2RX7ALDH1A1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150329483-A1 | Methods and Pharmaceutical Compositions for the Treatment of X-Linked Charcot-Marie-Tooth | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2015-11-19 | — | — | US | disclosed |
| WO-2014095757-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF X-LINKED CHARCOT-MARIE-TOOTH | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-06-26 | — | — | WO | disclosed |
| US-5245034-A | Compound having vessel smooth muscle relaxation activity | Hidaka, Kiroyoshi (JP) | 1993-09-14 | — | — | US | disclosed |
| US-5216150-A | Muscle relaxant; enzyme inhibitor and platelet aggutination inhibitor | Hidaka, Hiroyoshi (JP) | 1993-06-01 | — | — | US | disclosed |
| US-5081246-A | Isoquinolino sulfonamino derivatives | Hidaka, Hiroyoshi (JP) | 1992-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329483-A1 | Methods and Pharmaceutical Compositions for the Treatment of X-Linked Charcot-Marie-Tooth | PMP22, CAMK2G, CAMK2B | P2RX7 1693/4885ALDH1A1 4044/4885SMN1; SMN2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.